Oncogenic KRAS is notoriously difficult to target. Silenseed thinks its localized, sustained siRNA delivery technology, dubbed LODER, provides a viable strategy and also addresses issues of tissue targeting, cellular uptake and degradation in the blood associated with nucleic acid therapeutics.